Sugi Predict

Sugi Predict / Compounds / SCHEMBL125806

SCHEMBL125806

SCHEMBL125806

Cc1ccc2[nH]c(-c3ccccn3)nc2c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CBFB Q13951 10/20 1.00
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ NPC1 O15118 4/20 0.62
▸ RAB9A P51151 4/20 0.62
▸ HPGD P15428 3/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ TP53 P04637 2/20 0.62
▸ MAPT P10636 2/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ METAP2 P50579 8/20 0.58
▸ METAP1 P53582 7/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ PKM P14618 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ MTOR P42345 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL124191 0.83 CBFB (1.00) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL15780002 0.78 CBFB (0.69) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6373229 0.78 CBFB (0.63) CBFBNPC1RAB9A
SCHEMBL10351016 0.76 CBFB (0.61) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6885365 0.75 NPC1 (0.61) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL30692551 0.74 CBFB (1.00) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL125187 0.74 CBFB (1.00) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL125229 0.74 CBFB (1.00) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL124272 0.74 CBFB (0.68) CBFBSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL15780001 0.73 CBFB (0.75) CBFBSMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180004-B1 CANCER THERAPEUTICS UNIV VIRGINIA PATENT FOUNDATION (US) 2021-01-06 — — EP disclosed
EP-3670509-A1 INHIBITORS OF INV(16) LEUKEMIA The University of Virginia Patent Foundation (US) 2020-06-24 — — EP disclosed
US-10562890-B2 Cancer therapeutics UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2020-02-18 — — US disclosed
US-9926290-B2 Inhibitors of INV(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-03-27 — — US disclosed
US-9926290-B2 Inhibitors of INV(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-03-27 — — US disclosed
US-20170233375-A1 CANCER THERAPEUTICS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2017-08-17 — — US disclosed
US-20160096820-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2016-04-07 — — US disclosed
US-20160096820-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2016-04-07 — — US disclosed
US-9221764-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2015-12-29 — — US disclosed
US-9221764-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2015-12-29 — — US disclosed
US-20140243331-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-08-28 — — US disclosed
US-8748618-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-06-10 — — US disclosed
US-8748618-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-06-10 — — US disclosed
US-20120059003-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-03-08 — — US disclosed
US-20120059003-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-03-08 — — US disclosed
WO-2010132684-A9 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-01-06 — — WO disclosed
WO-2010132684-A2 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-11-18 — — WO disclosed
EP-0120396-B1 TEST STRIP FOR THE DETECTION OF LEUCOCYTES IN URINE MACHEREY-NAGEL & Co, Chemikalienhandel (DE) 1990-05-30 — — EP disclosed
US-4670402-A Use of benzimidazole derivatives for the detection of blood and other peroxidatically active substances in body fluids and excretion products MACHEREY-NAGEL & CO.-CHEMIKALIENHANDEL (DE) 1987-06-02 — — US disclosed
EP-0120396-A2 Test strip for the detection of leucocytes in urine MACHEREY-NAGEL & Co, Chemikalienhandel (DE) 1984-10-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233375-A1 CANCER THERAPEUTICS RUNX1, CBFB, MCL1 CBFB 2/4885SMN1; SMN2 2707/4885NPC1 3614/4885
US-20120059003-A1 INHIBITORS OF INV(16) LEUKEMIA FLI1, MCL1, CBFB CBFB 3/4885SMN1; SMN2 872/4885NPC1 1794/4885
US-20140243331-A1 INHIBITORS OF INV(16) LEUKEMIA FLI1, MCL1, CBFB CBFB 3/4885SMN1; SMN2 760/4885NPC1 1798/4885
US-10562890-B2 Cancer therapeutics RUNX1, CBFB, MCL1 CBFB 2/4885SMN1; SMN2 2707/4885NPC1 3614/4885
US-20160096820-A1 INHIBITORS OF INV(16) LEUKEMIA FLI1, MCL1, CBFB CBFB 3/4885SMN1; SMN2 760/4885NPC1 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.